Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Endocrine disruptor risk characterization: an EPA perspective

P A Fenner-Crisp1

  • 1Office of Pesticide Programs (7501C), U.S. Environmental Protection Agency, Washington, DC 20460, USA.

Regulatory Toxicology and Pharmacology : RTP
|August 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

FQPA science issues: common mechanism of toxicity and cumulative risk assessment.

Regulatory toxicology and pharmacology : RTP·2000
Same author

Endocrine modulators: risk characterization and assessment.

Toxicologic pathology·2000
Same author

Regulatory implications: U.S. Environmental Protection Agency.

Annals of the New York Academy of Sciences·1996
Same author

Impact of the Delaney Clause in the EPA.

Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie·1996
Same author

Pesticides--the NAS report: how can the recommendations be implemented?

Environmental health perspectives·1995
Same author

Evaluation of the carcinogenic potential of pesticides. 4. Chloroalkylthiodicarboximide compounds with fungicidal activity.

Regulatory toxicology and pharmacology : RTP·1993
Same journal

Applying the Omics Data Analysis Framework for Regulatory Application (R-ODAF) filtering criteria: A Case Study with 3-Methylcholanthrene.

Regulatory toxicology and pharmacology : RTP·2026
Same journal

Cardiovascular toxicity as a globally harmonized system hazard trait: The evidence and the path forward.

Regulatory toxicology and pharmacology : RTP·2026
Same journal

The NTP chronic inhalation study does not support an inherent lung cancer hazard of talc: Implications of lung particle overload and maximum tolerated dose.

Regulatory toxicology and pharmacology : RTP·2026
Same journal

Consideration of Carcinogenicity and Mode of Action Information by an Independent Expert Panel to Support Derivation of No-Significant-Risk-Level Values for Vinyl Acetate Monomer.

Regulatory toxicology and pharmacology : RTP·2026
Same journal

Which carcinogenicity study should I use? Automated identification of reliable studies.

Regulatory toxicology and pharmacology : RTP·2026
Same journal

Adoption of artificial intelligence in drug review across the lifecycle: Transformation of regulatory decision-making.

Regulatory toxicology and pharmacology : RTP·2026
See all related articles

Characterizing risks from endocrine-disrupting chemicals (EDCs) is challenging due to complex endocrine system interactions and developmental timing. Current risk assessment methods for hormonally mediated effects need adaptation as scientific understanding grows.

Area of Science:

  • Endocrinology
  • Toxicology
  • Risk Assessment

Background:

  • The endocrine system is a complex network of interacting systems with cyclical functions.
  • Assessing risks of endocrine-disrupting agents presents significant challenges for regulatory bodies.
  • Understanding the impact of timing and developmental stage on endocrine disruption is crucial.

Purpose of the Study:

  • To highlight the complexities in characterizing risks associated with endocrine-disrupting agents.
  • To review current practices for assessing hormonally mediated cancer and non-cancer effects.
  • To propose potential modifications to risk characterization approaches.

Main Methods:

  • Discussion of current risk assessment practices for endocrine disruptors.
  • Analysis of the unique challenges posed by the endocrine system's complexity.

Related Experiment Videos

  • Speculation on future adaptations based on evolving scientific knowledge.

    • Main Results:

    • Endocrine disruption risk assessment is complicated by system interdependencies and timing-dependent effects.
    • Concomitant exposures to endocrine-active substances are poorly understood.
    • Existing methods for cancer and non-cancer risk characterization require re-evaluation.

    Conclusions:

    • Risk characterization of endocrine-disrupting agents demands novel approaches.
    • Adapting current methodologies is essential to address the intricate nature of endocrine disruption.
    • Further research is needed to refine risk assessment strategies for these agents.